Jefferies Upgrades Bristol-Myers Squibb Co. (BMY) to Buy

Jefferies upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Buy with a price target of $69.00.

Analyst Jeffrey Holford commented, "We expect BMY to share the CTLA-4 combo IO opportunity in NSCLC with AZN, with key data from CM-568 and CM-227 securing its future in 2017. On this basis we see the PEG of 1.2 against the sector average of 1.9 as attractive and have upgraded the shares to Buy as a result."

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $58.62 yesterday.

You May Also Be Interested In

• Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
• BofA Securities Upgrades Timken (TKR) to Buy, 'Early innings of a transformation story'
• Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'